.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
REWIND randomized nearly 10,000 people with type 2 diabetes to weekly dulaglutide or placebo and followed them for a median of more than five years. Dulaglutide significantly reduced the composite of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death. Importantly, a substantial proportion of participants did not have established cardiovascular disease at baseline, making the results relevant to primary prevention as well as secondary prevention. For internists, REWIND supports selecting glucose-lowering therapy with attention to cardiovascular risk even when HbA1c is not markedly elevated. As with other GLP-1 receptor agonists, gastrointestinal adverse effects and the need for sustained treatment should be discussed. The trial also demonstrates that cardiovascular outcomes are not limited to patients with advanced diabetes. Risk assessment should therefore begin early, with treatment decisions informed by obesity, blood pressure, kidney disease, lipid status and cardiovascular history rather than glycemic numbers alone.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
REWIND randomized nearly 10,000 people with type 2 diabetes to weekly dulaglutide or placebo and followed them for a median of more than five years. Dulaglutide significantly reduced the composite of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death. Importantly, a substantial proportion of participants did not have established cardiovascular disease at baseline, making the results relevant to primary prevention as well as secondary prevention. For internists, REWIND supports selecting glucose-lowering therapy with attention to cardiovascular risk even when HbA1c is not markedly elevated. As with other GLP-1 receptor agonists, gastrointestinal adverse effects and the need for sustained treatment should be discussed. The trial also demonstrates that cardiovascular outcomes are not limited to patients with advanced diabetes. Risk assessment should therefore begin early, with treatment decisions informed by obesity, blood pressure, kidney disease, lipid status and cardiovascular history rather than glycemic numbers alone.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
